scholarly journals Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma

BMC Cancer ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Koji Inaba ◽  
Ryoji Kushima ◽  
Naoya Murakami ◽  
Yuuki Kuroda ◽  
Ken Harada ◽  
...  
Blood ◽  
2017 ◽  
Vol 130 (5) ◽  
pp. 590-596 ◽  
Author(s):  
Jonathan W. Friedberg

Abstract The 2016 revision of the World Health Organization (WHO) classification for lymphoma has included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with translocations involving myc and bcl-2 or bcl-6. These lymphomas, which occur in <10% of cases of diffuse large B-cell lymphoma, have been referred to as double-hit lymphomas (or triple-hit lymphomas if all 3 rearrangements are present). It is important to differentiate these lymphomas from the larger group of double-expressor lymphomas, which have increased expression of MYC and BCL-2 and/or BCL-6 by immunohistochemistry, by using variable cutoff percentages to define positivity. Patients with double-hit lymphomas have a poor prognosis when treated with standard chemoimmunotherapy and have increased risk of central nervous system involvement and progression. Double-hit lymphomas may arise as a consequence of the transformation of the underlying indolent lymphoma. There are no published prospective trials in double-hit lymphoma, however retrospective studies strongly suggest that aggressive induction regimens may confer a superior outcome. In this article, I review my approach to the evaluation and treatment of double-hit lymphoma, with an eye toward future clinical trials incorporating rational targeted agents into the therapeutic armamentarium.


Blood ◽  
2016 ◽  
Vol 127 (12) ◽  
pp. 1564-1574 ◽  
Author(s):  
Tibor Bedekovics ◽  
Sajjad Hussain ◽  
Andrew L. Feldman ◽  
Paul J. Galardy

Key Points The neuronal marker UCH-L1 is induced in, and specifically augments the oncogene-induced transformation of, GCB cells. High levels of UCHL1 identify patients with GC DLBCL with an increased risk for poor outcomes.


2003 ◽  
Vol 21 (9) ◽  
pp. 1782-1789 ◽  
Author(s):  
K. Seidemann ◽  
M. Tiemann ◽  
I. Lauterbach ◽  
G. Mann ◽  
I. Simonitsch ◽  
...  

Purpose: Primary mediastinal large B-cell lymphoma with sclerosis (PMLBL) is a rare entity of non-Hodgkin’s lymphoma (NHL) arising from thymic mature B cells. Optimal treatment strategies remain to be established, especially in pediatric patients. Patients and Methods: This study analyzes clinical characteristics and treatment outcome of 30 pediatric patients with PMLBL, diagnosed in multicenter therapy NHL–Berlin-Frankfurt-Münster Group (BFM) trials. Treatment was stratified by stage and serum lactate dehydrogenase (LDH) and consisted of four to six 5-day courses of chemotherapy using steroids, oxazaphosphorine alkylating agents, methotrexate, cytarabine, etoposide, and doxorubicin. Radiation was not part of the protocol. Results: From April 1986 to August 1999, 1,650 patients with newly diagnosed NHL were enrolled in the NHL-BFM trials; 30 patients (1.8%) had PMLBL. Median age was 14.3 years (range, 1.4 to 16.7 years); 15 patients were male and 15 patients were female. With a median observation time of 5 years (range, 1 to 12 years), probability of event-free survival (pEFS) at 5 years was 0.70 (SE, 0.08). Two patients erroneously diagnosed as T-cell NHL received non–B-cell therapy and died from progress of disease. Events in 28 patients receiving B-cell therapy included early progress during therapy (n = 1) and relapse (n = 6). Residual mediastinal masses were present in 23 patients after two courses of therapy and in 15 patients after the end of therapy. LDH ≥ 500 U/L was associated with increased risk of failure in multivariate analysis. Conclusion: PMLBL mainly is found in adolescents. Dose-intense chemotherapy including high-dose methotrexate yields a pEFS at 5 years of 0.70 (SE, 0.08). LDH is of prognostic value in pediatric patients with PMLBL.


2017 ◽  
Vol 17 (2) ◽  
pp. 180 ◽  
Author(s):  
Riwa Sakr ◽  
Marcel Massoud ◽  
Georges Aftimos ◽  
Georges Chahine

2014 ◽  
Vol 75 (12) ◽  
pp. 3265-3270
Author(s):  
Ken IMAIZUMI ◽  
Tetunori YOSHIMURA ◽  
Kazuo MOTOYAMA ◽  
Takayuki HIRANO ◽  
Takuya NAKADA ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1967
Author(s):  
Pauli Vähämurto ◽  
Marjukka Pollari ◽  
Michael R. Clausen ◽  
Francesco d’Amore ◽  
Sirpa Leppä ◽  
...  

Low absolute lymphocyte counts (ALC) and high absolute monocyte counts (AMC) are associated with poor survival in patients with diffuse large B-cell lymphoma (DLBCL). We studied the prognostic impact of the ALC and AMC in patients with testicular DLBCL (T-DLBCL). T-DLBCL patients were searched using Southern Finland University Hospital databases and the Danish lymphoma registry. The progression free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier and Cox proportional hazards methods. We identified 178 T-DLBCL patients, of whom 78 (44%) had a low ALC at diagnosis. The ALC did not correlate with survival in the whole cohort. However, among the patients treated with rituximab (R) containing regimen, a pre-therapeutic low ALC was associated with an increased risk of progression (HR 1.976, 95% CI 1.267–3.086, p = 0.003). Conversely, intravenous (iv) CNS directed chemotherapy translated to favorable outcome. In multivariate analyses, the advantage of an iv CNS directed chemotherapy was sustained (PFS, HR 0.364, 95% CI 0.175–0.757, p = 0.007). The benefit of R and intravenous CNS directed chemotherapy was observed only in non-lymphopenic patients. The AMC did not correlate with survival. A low ALC is an adverse prognostic factor in patients with T-DLBCL. Alternative treatment options for lymphopenic patients are needed.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12072-12072
Author(s):  
Yvonne M. Geurts ◽  
Suzanne I.M. Neppelenbroek ◽  
Cynthia So-Osman ◽  
Joost S.P. Vermaat ◽  
Dick Johan van Spronsen ◽  
...  

12072 Background: Due to the historically less favorable prognosis of diffuse large B cell lymphoma (DLBCL), the burden of second malignant neoplasms (SMNs) has been rarely studied in DLBCL survivors. However, radiotherapy and chemotherapy may increase SMN risk among DLBCL patients. Anthracyclines may increase the risk of hematological malignancies, but it is not clear whether they also increase solid cancer risk. Methods: We established a multicenter cohort of 2,384 5-year DLBCL survivors treated at ages 15-60 years with radiotherapy and/or immuno-chemotherapy between 1989 and 2012. Observed numbers of SMNs were compared with expected cancer incidence in the general population to compute standardized incidence ratios (SIRs), absolute excess risks (AERs, per 10.000 person-years) and cumulative incidence. Treatment specific incidence was compared with general population rates and assessed within the cohort using Cox regression. Results: Most DLBCL patients received alkylating agents (95%), anthracycline-containing chemotherapy (95%) or radiotherapy (61%); 46% received rituximab. Median follow-up was 13.3 years; 17% of patients was followed ≥20 years. In total, 308 5-year survivors developed an invasive SMN (SIR 1.6; 95% confidence interval (CI), 1.4 to 1.8), translating into 56.2 excess cancers per 10.000 person-years (see Table for specific sites). In 20-year survivors of DLBCL, the SIR was 1.8 (95% CI 1.3-2.6). The 20-year cumulative incidence of any SMN was 18.7% (95% CI 16.5-21.0%). The SIR for any SMN was higher in patients <40 years at first treatment (SIR ≤40 years: 2.8, SIR >40 years: 1.4; p<0.001). Treatment specific results will be presented at ASCO21. Conclusions: DLBCL survivors experience higher risk of SMNs than the general population. Identification of patients at increased risk could improve follow-up care.[Table: see text]


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4424-4424
Author(s):  
Abdul K. Siraj ◽  
Rong Bu ◽  
Mona Ibrahim ◽  
Maha Al-Rasheed ◽  
Jehad Abubaker ◽  
...  

Abstract Diffuse large B-Cell Lymphoma (DLBCL) is one of the most common types of non-Hodgkin lymphoma (NHL) and an increased incidence has been reported during the past 30 years. The cause of this remains unknown but population-based studies suggest a relationship with exposure to certain environment carcinogens. Particularly, exposure to asbestos, benzene, industrial and agricultural toxins has been implicated as possible cause of the disease. The xenobiotic enzyme system that enables us to detoxify these types of carcinogens exhibits identifiable genetic polymorphisms that are associated with variations in functional activity. These genetic differences are highly race specific and have never been screened in the Saudi DLBCL patients. We propose that individuals with certain xenobiotic gene polymorphisms may modify the risk to develop DLBCL than other individuals exposed to similar environmental conditions. Furthermore, the demonstration of a relationship between identifiable xenobiotic systems and the development of DLBCL would contribute to our understanding of the pathogenesis of this and related disorder. We have therefore investigated the association between polymorphisms in genes encoding xenobiotics-metabolizing enzymes, including CYP1A1, GSTT1, GSTM1, GSTP1, MTHFR and NQO1, using PCR-RELP, and risk to develop DLBCL in a population-based study (513 Saudi controls and 182 Saudi DLBCL patients). MTHFR 1298 CC (OR=4.23) and C allele (OR = 1.73) showed an increased risk, and combined genotype CCCC among intermediate MTHFR activity group was associated with 3.489 fold increase and CTCC among low MTHFR activity group was related to 9.515 fold higher risk to develop DLBCL compared with full MTHFR enzyme activity. The genotype of NQO1 TT was associated with 1.86 fold while CYP1A 4887 AA showed 2.34 fold higher risk to develop DLBCL compared with wild type. GSTP1 1578 GG genotype (OR=0.368) was shown to be protective against DLBLC. Although the GSTT1 null was found to be a risk factor (OR=11.948) to develop DLBCL but double null of GSTT1 and GSTM1 also showed 3.087 fold higher risk to develop DLBCL. Our findings suggest that polymorphisms of xenobiotic metabolizing enzyme genes modify the individual susceptibility to develop DLBCL in the Saudi population. Although no dose-response relationship was found for multiple genes, future large-scale study is called for to confirm the role of polymorphisms of above genes and their combination on modification of susceptibility to DLBCL in Saudi Arabia. Distribution of polymorphisms in healthy population and lymphoma patients. Polymorphism Genotype Control Patients P OR MTHFR A1298C AA 239(46.8%) 38(33.6%) AC 220(43.1%) 40(35.4%) CC 52(10.2%) 35(31%) <0.001 4.23 AC+CC 272(53.2%) 75(66.4%) 0.012 1.73 MTHFR C677T+A1298C Intermediate Activity CCCC 45(8.8%) 22(27.8%) <0.001 3.48 Low Activity CTCC 6(1.2%) 8(10%) <0.001 9.51 TTAC 0 2(2.5%) 0.017 NQO1 C609T CC 295(58.5%) 94(62.7%) CT 177(35.1%) 37(24.7%) 0.051 0.65 TT 32(6.4%) 19(8.7%) 0.059 1.86 CT+TT 209(41.5%) 56(37.3%) GSTP1 A1578G AA 170(33.5%) 56(35%) AG 271(53.5%) 96(60%) GG 66(13%) 8(5%) 0.013 0.37 AG+GG 337(66.5%) 104(65%) GSTT1 P 385(75%) 36(20.1%) D 128(25%) 143(79.9%) <0.001 11.95 GSTT1+GSTM1 Present 423(82.8%) 109(60.9%) Double Null 88(17.2%) 70(39.1%) <0.001 3.09 CYP1A1 C4887A CC 331(64.8%) 102(63%) CA 162(31.7%) 47(29%) AA 18(3.5%) 13(8%) 0.030 2.34


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4286-4286
Author(s):  
Jeong-Eun Kang ◽  
In-Suk Kim ◽  
Nam-Hee Kim ◽  
Min Kyoung Kim

Abstract Introduction There is growing evidence linking genetic variations of immune regulation genes to non-Hodgkin lymphoma (NHL) etiology. In a large consortial study, it has been recently reported that an increased risk for NHL, especially the major lymphoma subtype diffuse large B-cell lymphoma (DLBCL), with genetic variations in immune regulatory genes that mediate inflammation and autoimmunity. To complement ongoing agnostic approaches for identifying susceptibility genes, we evaluated 57 genetic variations of 7 candidate genes, and their relation to risk for DLBCL in Koreans. Methods The case-control series consisted of 192 de novo DLBCL treated at five hospitals throughout Korea from August 2001 through August 2009 and 192 individuals from the population with age and gender matched healthy volunteers. The DNA samples were genotyped using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (Sequenom, Inc., San Diego, CA). We genotyped 11 haplotype-tagging SNPs (htSNPs) of spleen tyrosine kinase (STK), 9 htSNPs of Fc fragment of IgG, low affinity IIa, receptor (FCGR2A), 3 htSNPs of Fc fragment of IgG, low affinity IIIa, receptor (FCGR3A), 15 htSNPs of interferon regulatory factor 4 (IRF4), 9 htSNPs of interleukin 7 receptor (IL7R), 7 htSNPs of interleukin 10 (IL10), and 3 htSNPs of tumor necrosis factor (TNF) genes. We used logistic regression to evaluate the association between genotypes and haplotypes with DLBCL. For DLBCL subtypes, we conducted polytomous multivariate unconditional logistic regression (adjusted for sex, race, age). We calculated P-trends under the co-dominant model for each SNP. The haplotypes were reconstructed according to the genotyping data and the linkage disequilibrium status of these SNPs. Results We did not find significant associations between the htSNPs of FCGR2A, FCGR3A, IRF4, IL7R, and TNF genes and the risk of DLBCL. However, the minor allele heterozygotes of the rs3021094 htSNP of IL10 gene (P-trend = 0.028) and the rs2991216 htSNP of the SYK gene (P-trend = 0.035) showed an increased risk of DLBCL. On 10-million permutation testing, the haplotype including rs3021094 variant allele of IL10 gene was significantly associated with an increased risk of DLBCL (P = 0.001), however, the haplotype including rs2991216 variant allele of STK gene was statistically insignificant (P = 0.055). Conclusions This study presents several novel aspects of the genetic susceptibility to develop DLBCL. Although this study did not show statistically significant association between STK htSNPs and risk for DLBCL on 10-millinon permutation testing, we demonstrated that genetic variants and haplotypes of IL10 gene showed the significantly increased risk for DLBCL. Larger studies that focus on the role of the STK and IL10 genes will support to confirm causal variants to develop diffuse large B-cell lymphoma. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document